Horizon Investments LLC Purchases 559 Shares of Eli Lilly and Company (NYSE:LLY)

Key Points

• Horizon Investments LLC increased its stake in Eli Lilly and Company by 6.3%, acquiring 559 additional shares, bringing their total holding to 9,491 shares valued at $7,839,000.
• Eli Lilly reported a quarterly EPS of $6.31, exceeding analysts' expectations of $5.59, with revenue of $15.56 billion for the quarter, marking a 37.6% increase year-over-year.
$1.50, set to be paid on September 10th, which represents an annualized dividend of $6.00 and a yield of 0.9%.

Horizon Investments LLC grew its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 6.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,491 shares of the company's stock after purchasing an additional 559 shares during the quarter. Horizon Investments LLC's holdings in Eli Lilly and Company were worth $7,839,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Azimuth Capital Investment Management LLC grew its stake in shares of Eli Lilly and Company by 15.0% in the first quarter. Azimuth Capital Investment Management LLC now owns 74,600 shares of the company's stock worth $61,613,000 after acquiring an additional 9,757 shares during the last quarter. Trivium Point Advisory LLC grew its stake in shares of Eli Lilly and Company by 10.7% in the first quarter. Trivium Point Advisory LLC now owns 2,873 shares of the company's stock worth $2,373,000 after acquiring an additional 278 shares during the last quarter. Kovitz Investment Group Partners LLC grew its stake in shares of Eli Lilly and Company by 63.3% in the first quarter. Kovitz Investment Group Partners LLC now owns 47,584 shares of the company's stock worth $39,300,000 after acquiring an additional 18,443 shares during the last quarter. Cookson Peirce & Co. Inc. grew its stake in shares of Eli Lilly and Company by 17.3% in the first quarter. Cookson Peirce & Co. Inc. now owns 14,258 shares of the company's stock worth $11,776,000 after acquiring an additional 2,100 shares during the last quarter. Finally, Oak Ridge Investments LLC grew its stake in shares of Eli Lilly and Company by 6.1% in the first quarter. Oak Ridge Investments LLC now owns 58,613 shares of the company's stock worth $48,409,000 after acquiring an additional 3,370 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 3.8%

Shares of NYSE LLY opened at $685.27 on Friday. The stock has a market cap of $648.58 billion, a PE ratio of 44.79, a PEG ratio of 0.93 and a beta of 0.44. The business has a fifty day moving average of $765.92 and a two-hundred day moving average of $795.40. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%. The business's revenue was up 37.6% on a year-over-year basis. During the same period last year, the business earned $3.92 earnings per share. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's payout ratio is currently 39.22%.

Insiders Place Their Bets

In other Eli Lilly and Company news, Director Gabrielle Sulzberger purchased 117 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, with a total value of $75,018.06. Following the completion of the acquisition, the director directly owned 2,703 shares of the company's stock, valued at $1,733,109.54. This represents a 4.52% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Daniel Skovronsky purchased 1,000 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president directly owned 137,660 shares of the company's stock, valued at $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 4,514 shares of company stock valued at $2,894,841 over the last three months. Company insiders own 0.13% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on LLY. HSBC downgraded shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their price objective for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. Leerink Partnrs downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. Hsbc Global Res downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research note on Monday. Finally, Leerink Partners reiterated a "market perform" rating and set a $715.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 7th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $964.88.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.